Investor Presentaiton
Investor Presentation
First nine months of 2018
The obesity pipeline consists of projects addressing both
appetite reduction and energy expenditure
How to address obesity
from a medical perspective
Slide 95
Novo Nordisk obesity products and pipeline
Projects:
Status:
2018 expected:
SaxendaⓇ
Weight
reduction by
reducing
food intake
increasing
energy
expenditure
Weight
reduction by
semaglutide - QW GLP-1
AM833 amylin analogue
PYY1562 - PYY analogue
NN9277-GG-co-agonist
Launched
Phase 3
Phase 1b
Phase 2 ready
Phase 1b
Phase 1b1
Phase 1a
Phase 1b
NN9423 - Tri-agonist 1706
PYY1875 - PYY analogue
Phase 1a
Phase 1b
New
Phase 1a²
Appetite reduction
changing
diabetes
Impact on metabolic
changes to increase lipid
and glucose metabolism
Appetite reduction
Energy expenditure
Appetite reduction and energy expenditure
1 Phase 1b completed with monotherapy, phase 1b in combination with semaglutide planned for 2018
2 Monotherapy and in combination with semaglutide
Phase 1a: Single-dose trials; Phase 1b: Multiple-dose trials
QW: Once-weekly
novo nordiskView entire presentation